The R&D team confirmed that both the capture and detection antibodies are polyclonal goat anti-human Granulysin. The immunogen is recombinant Human Granulysin (aa23-145). The antibodies have not been tested for reactivity to different isoforms of Granulysin.
HCKP2-11K
MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel
Configurable Human Immuno-Oncology Checkpoint Protein 31-Plex Panel 2
Sign In to View Organizational & Contract Pricing.
To order a Milliplex® kit, please search for your analyte of interest.
About This Item
NACRES:
NA.47
UNSPSC Code:
12161503
Skip To
species reactivity
human
technique(s)
multiplexing: suitable
input
serum plasma (Cell culture, cell culture supernatants)
packaging
pkg of 1 ea
manufacturer/tradename
Milliplex®
detection method
fluorometric (Luminex® xMAP® technology)
shipped in
wet ice
storage temp.
2-8°C
1 of 4
This Item | HCKP1-11K | HCKP1-11K-PX17 | HCKP1-11K-PXBK17 |
|---|---|---|---|
| species reactivity human | species reactivity human | species reactivity human | species reactivity human |
| manufacturer/tradename Milliplex® | manufacturer/tradename Milliplex® | manufacturer/tradename Milliplex® | manufacturer/tradename Milliplex® |
| technique(s) multiplexing: suitable | technique(s) multiplexing: suitable | technique(s) multiplexing: suitable | technique(s) multiplexing: suitable |
| detection method fluorometric (Luminex® xMAP®) | detection method fluorometric (Luminex® xMAP®) | detection method fluorometric (Luminex® xMAP®) | detection method fluorometric (Luminex® xMAP®) |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C |
Features and Benefits
- 31-Plex Immune Checkpoint Profiling: Simultaneously quantify 31 biomarkers (e.g., IDO1, B7-H3, Granzyme B) in a single assay, covering co-stimulatory, co-inhibitory, and tumor microenvironment targets.
- Luminex® xMAP® Technology: High-throughput, bead-based multiplexing for reliable detection of soluble checkpoint proteins in serum, plasma, and culture samples.
- Configurable Panels: Select specific analytes (e.g., Arginase-1, Siglec-7) to tailor the kit to your research focus, optimizing cost and experimental design.
- Broad Biomarker Coverage: Targets novel checkpoints (VISTA, FGL1) and established markers (PD-L1 alternatives like B7-H4), ideal for exploratory immunotherapy research.
- Accelerate Translational Oncology: Study immune evasion mechanisms via tumor microenvironment markers (Galectin-3, E-Cadherin). Identify predictive biomarkers for checkpoint inhibitor response (e.g., IDO1, Granzyme B). Explore emerging therapeutic targets like VISTA (B7-H5) and CD73 (5′-NT).
- Therapeutic Relevance: Directly supports immune-oncology drug development (e.g., anti-CD73, anti-B7-H3 therapies).
General description
Immune checkpoint proteins, such as co-inhibitory molecules (e.g., IDO1, B7-H3) and co-stimulatory signals (e.g., OX40, 4-1BB), orchestrate immune activation and tolerance, playing dual roles in tumor immune evasion and therapeutic response. While inhibitors targeting CTLA-4 and PD-1/PD-L1 have revolutionized cancer treatment, resistance and variable patient outcomes underscore the need to explore novel checkpoints (VISTA, CD73) and tumor microenvironment mediators (Galectin-3, Arginase-1). Emerging research highlights soluble isoforms and lesser-studied membrane proteins as predictive biomarkers and therapeutic targets, driving efforts to decode their spatial, temporal, and combinatorial roles in immune suppression. This multifaceted landscape demands high-dimensional profiling to unravel mechanisms of resistance, optimize combination therapies, and identify sample subsets poised to benefit from next-gen immunotherapies.
Legal Information
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Application
MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 31 analytes in human serum, plasma, and cell culture supernatants.
Analytes included: 4-1BBL/TNFSF9, 5′-NT/CD73 (5′-nucleotidase), APRIL (TNFSF13), Arginase-1, B7-H2/ICOSL (Inducible T cell costimulator ligand), B7-H3/CD276, B7-H4/VTCN1 (V-set domain-containing T-cell activation inhibitor 1), B7-H5/VISTA (V-set immunoregulatory receptor), B7-H6 (Natural killer cell cytotoxicity receptor 3 ligand), BAFF/BLyS (TNFSF13B), CD25/IL-2Rα (Interleukin-2 receptor alpha), CD30/TNFRSF8, CD40L (CD40 ligand), CD137/4-1BB (TNFRSF9), CD226/DNAM-1 (DNAX accessory molecule 1), E-Cadherin, FGL1/Hepassocin (Fibrinogen-like protein 1), Galectin-1 (Gal-1), Galectin-3 (Gal-3), Granulysin, Granzyme B, IDO1 (Indoleamine 2,3-dioxygenase 1), MICA (MHC class I polypeptide-related sequence A), MICB (MHC class I polypeptide-related sequence B), Nectin-2 (PVRL2, CD112), Nectin-4 (PVRL4), OX40/CD134 (TNFRSF4), Perforin, PVR/CD155 (Poliovirus receptor cell adhesion molecule), Siglec-7 (Sialic acid-binding Ig-like lectin 7, CD328), Siglec-9 (Sialic acid-binding Ig-like lectin 9, CD329)
Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Analytes included: 4-1BBL/TNFSF9, 5′-NT/CD73 (5′-nucleotidase), APRIL (TNFSF13), Arginase-1, B7-H2/ICOSL (Inducible T cell costimulator ligand), B7-H3/CD276, B7-H4/VTCN1 (V-set domain-containing T-cell activation inhibitor 1), B7-H5/VISTA (V-set immunoregulatory receptor), B7-H6 (Natural killer cell cytotoxicity receptor 3 ligand), BAFF/BLyS (TNFSF13B), CD25/IL-2Rα (Interleukin-2 receptor alpha), CD30/TNFRSF8, CD40L (CD40 ligand), CD137/4-1BB (TNFRSF9), CD226/DNAM-1 (DNAX accessory molecule 1), E-Cadherin, FGL1/Hepassocin (Fibrinogen-like protein 1), Galectin-1 (Gal-1), Galectin-3 (Gal-3), Granulysin, Granzyme B, IDO1 (Indoleamine 2,3-dioxygenase 1), MICA (MHC class I polypeptide-related sequence A), MICB (MHC class I polypeptide-related sequence B), Nectin-2 (PVRL2, CD112), Nectin-4 (PVRL4), OX40/CD134 (TNFRSF4), Perforin, PVR/CD155 (Poliovirus receptor cell adhesion molecule), Siglec-7 (Sialic acid-binding Ig-like lectin 7, CD328), Siglec-9 (Sialic acid-binding Ig-like lectin 9, CD329)
Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Disclaimer
For research use only. Not for use in diagnostic procedures.
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
signalword
Danger
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
target_organs
Respiratory Tract
Storage Class
10 - Combustible liquids
wgk
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Discover the benefits of MILLIPLEX® multiplex assays, based on Luminex® xMAP® multiplex assay technology, that provide consistent, high-quality results and see how these multiplex biomarker Luminex® assays are being used to advance research.
Research evaluating immune checkpoints may help identify those likely to benefit from PD-1/PD-L1 immunotherapy and reveal new immunotherapy targets for future investigation. See how the MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 2 was used to multiplex immune checkpoint molecules for NSCLC research.
Cancer biomarker detection through MILLIPLEX® multiplex cancer assays can accelerate studies of tumorigenic processes helping advance cancer research.
Discover cancer research resources with modeling and profiling tools for cell culture, genomics, biomarkers, and more to help maximize your cancer research.
-
What is the specificity of the Granulysin antibody pair in the Milliplex Human Immuno-oncology Checkpoint Protein Panel?
1 answer-
Helpful?
-
-
How many samples can I analyze with one multiplex kit including all controls and assuming that I will have 5 different time points were I will need to analyze samples immediately?
1 answer-
The end-user can analyze 38 samples in duplicates.
Helpful?
-
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service